In 2023, the mortality rate for malignant neoplasms among women in the US was recorded at approximately 168.4 deaths per hundred thousand women. The forecast for 2024 to 2028 indicates a gradual decline in mortality rates, with a year-on-year decrease averaging around 0.36%. This trend reflects advancements in early detection, improved treatment options, and better access to healthcare. Over the five-year forecast period, the compound annual growth rate (CAGR) shows a negative trajectory, supporting a consistent reduction in mortality rates.
Future trends to watch for include the impact of personalized medicine, potential breakthroughs in cancer immunotherapy, and the influence of public health initiatives aimed at cancer prevention. Monitoring these factors will be crucial in understanding the evolving landscape of cancer mortality rates.
